Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives $24.67 Average PT from Brokerages

Capricor Therapeutics, Inc. (NASDAQ:CAPR – Get Free Report) has been assigned a consensus recommendation of “Buy” from the nine analysts that are covering the stock, MarketBeat reports. Eight research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among […]

Leave a Reply

Your email address will not be published.

Previous post Brokerages Set Akero Therapeutics, Inc. (NASDAQ:AKRO) Target Price at $82.50
Next post Organon & Co. (NYSE:OGN) Receives $18.00 Average Target Price from Analysts